AstraZeneca Canada Inc. expands product portfolio to include vaccines
The submission is based on data from 73 global clinical and U.S. post-marketing studies of more than 141,000 subjects ranging in age from seven weeks to 97 years and conducted in 38 countries. During the 2004 to 2005 flu season, a large study was completed comparing FluMist, administered as a mist sprayed into the nose, to the injectable flu shot. The study included more than 8,000 children, of which more than 4,000 were between two to five years of age and showed that the group of children who received FluMist had significantly fewer cases of flu than the group who received the injectable flu shot.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.